Masseter hypertrophy is mostly idiopathic, rare, and occurs with no cause. It is an enlargement of one or both masseter muscles. Many of the patients develop this enlargement of the masseter muscles, because of having bruxism or teeth grinding during sleep. This makes the lower face become very broad and alters the proportion of the upper and the lower face, thereby impacting the beauty of the face.
Most patients complain of facial asymmetry; however, symptoms such as trismus, protrusion, and bruxism may also occur. Dr Debraj Shome, senior Cosmetic & Reconstructive Surgeon and Dr. Rinky Kapoor, a dermatologist at The Esthetic Clinics conducted a study to evaluate the efficacy of Xeomin treatment in the long‐term management of bilateral masseter hypertrophy in Asian Indian patients that can allow correcting the asymmetrical face non surgically.
Nowadays, the trends are changing and many patients are opting for nonsurgical or minimally invasive options for reshaping the face. Obviously, non-surgical treatment involves no downtime and also has zero risks.
Non-invasive treatments such as incobotulinumtoxinA (Xeomin) treatment is a preferred modality for reducing the volume of the muscle and therefore reducing the width of the masseter muscle.
A total of 30 patients was enrolled in the study and was injected with 30 U Xeomin on each side of the face, at baseline. Fifteen patients received a second session of Xeomin injection at 12th week, and the remaining 15 patients received an additional third session, at 12th and 24th weeks post the first injection, respectively. Follow‐up was done at 4tth, 12th‐, 24th‐, and 36th‐week and at first‐ and second‐year follow‐ups.
For the patients who received two injections, the maximum reduction of 26.85% in the size of the masseter muscle was observed at 24th week, which was maintained as a 20.04% reduction until the second follow‐up year.
The patients who received three injections exhibited a very high reduction of 43.12% of masseter volume at 36th week, which was maintained at 38.72 % until the second follow‐up year. Three sessions of Xeomin injections were proved to be more effective in the long‐term maintenance of reduced masseter volume than 2 sessions of injections.
This first-ever long-term total on the use of Xeomin in Masseter Hypertrophy was published in the Journal of Cosmetic Dermatology, one of America’s top Dermatology Journals. Dr. Debraj Shome, Director, The Esthetic Clinics and renowned dermatologist Dr. Rinky Kapoor have published their research in one of the most respected, peer-reviewed journals named Journal of Cosmetic Dermatology.
Dr Debraj Shome, who is a renowned Cosmetic Surgeon, said, “Many Indian patients come to us with the problem of Masseter hypertrophy. This is a characteristic condition resulting from an increase in the size of the muscle mass, that can spoil the appearance of the face. It can also lead to swelling that can be seen in the lower face region. The Xeomin injections can come to the rescue of these patients who want to get rid of that excess muscle mass and enhance their facial appearance.”
“Xeomin injections were found to be effective in the long‐term management of bilateral masseter hypertrophy. To the best of our knowledge, this is the first of its kind paper, which evaluates the long‐term effects of Xeomin injections for the treatment of masseter hypertrophy. It is completely safe with no side-effects and is beneficial in long -term maintenance of desired facial contours and patient satisfaction. It is available at one-tenth of the cost of surgery. This makes the treatment affordable and accessible to the patients,” concluded Dr Rinky Kapoor, Dermatologist, and dermato surgeon.
